Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5912146, 10 pages
http://dx.doi.org/10.1155/2016/5912146
Clinical Study

Folic Acid Supplementation Mitigates Alzheimer’s Disease by Reducing Inflammation: A Randomized Controlled Trial

1School of Nursing, Tianjin Medical University, Tianjin, China
2Department of Neurology, Huanhu Hospital, Tianjin, China
3Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China
4Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin, China
5Aging Research Centre, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden

Received 4 January 2016; Revised 6 March 2016; Accepted 4 April 2016

Academic Editor: Mukesh Kumar

Copyright © 2016 Hui Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. A. Evans, H. H. Funkenstein, M. S. Albert et al., “Prevalence of Alzheimer's disease in a community population of older persons, higher than previously reported,” The Journal of the American Medical Association, vol. 262, no. 18, pp. 2551–2556, 1989. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Y. Chan, J. J. Wu, L. Liu et al., “Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis,” The Lancet, vol. 381, no. 9882, pp. 2016–2023, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. L. Masters, R. Cappai, K. J. Barnham, and V. L. Villemagne, “Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics,” Journal of Neurochemistry, vol. 97, no. 6, pp. 1700–1725, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Chouliaras, D. Mastroeni, E. Delvaux et al., “Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients,” Neurobiology of Aging, vol. 34, no. 9, pp. 2091–2099, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Gezen-Ak, E. Dursun, H. Hanağası et al., “BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment,” Journal of Alzheimer's Disease, vol. 37, no. 1, pp. 185–195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. U. N. Das, “Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease—but how and why?” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 78, no. 1, pp. 11–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Chen, S. Liu, L. Ji et al., “Associations between Alzheimer’s disease and blood homocysteine, vitamin B12, and folate: a case-control study,” Current Alzheimer Research, vol. 12, no. 1, pp. 88–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Clarke, A. D. Smith, K. A. Jobst, H. Refsum, L. Sutton, and P. M. Ueland, “Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease,” Archives of Neurology, vol. 55, no. 11, pp. 1449–1455, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Postiglione, G. Milan, A. Ruocco, G. Gallotta, G. Guiotto, and G. Di Minno, “Plasma folate, vitamin B12, and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. A case-control study,” Gerontology, vol. 47, no. 6, pp. 324–329, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. McMahon, T. J. Green, C. M. Skeaff, R. G. Knight, J. I. Mann, and S. M. Williams, “A controlled trial of homocysteine lowering and cognitive performance,” The New England Journal of Medicine, vol. 354, no. 26, pp. 2764–2772, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Durga, M. P. van Boxtel, E. G. Schouten et al., “Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial,” The Lancet, vol. 369, no. 9557, pp. 208–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Zheng, M. Zhang, J. Yang et al., “Relationship between blood levels of methyl donor and folate and mild cognitive impairment in Chinese patients with type 2 diabetes: a case-control study,” Journal of Clinical Biochemistry and Nutrition, vol. 54, no. 2, pp. 122–128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. C. R. Jack Jr., M. S. Albert, D. S. Knopman et al., “Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's and Dementia, vol. 7, no. 3, pp. 257–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Feng, X. Q. Han, J. Chen, L. Shang, and J. Li, “Application of the activities of daily living rating scale in screening dementia,” J Clin Psychol Med, vol. 14, pp. 193–194, 2004. View at Google Scholar
  15. D. Papandreou, I. Mavromichalis, A. Makedou, I. Rousso, and M. Arvanitidou, “Total serum homocysteine, folate and vitamin B12 in a Greek school age population,” Clinical Nutrition, vol. 25, no. 5, pp. 797–802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. E. P. Quinlivan, “In vitamin B12 deficiency, higher serum folate is associated with increased homocysteine and methylmalonic acid concentrations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, article E7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Poirier, C. K. Wise, R. R. Delongchamp, and R. Sinha, “Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, and homocysteine: correlations with diet,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 6, pp. 649–655, 2001. View at Google Scholar · View at Scopus
  18. Z. Q. Sun, Medical Statistics, People's Medical Publishing House (PMPH), Beijing, China, 2nd edition, 2013.
  19. C. Ballard, M. Margallo-Lana, E. Juszczak et al., “Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial,” The British Medical Journal, vol. 330, no. 7496, pp. 874–877, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. R. J. Berry, Z. Li, J. D. Erickson et al., “Prevention of neural-tube defects with folic acid in China,” The New England Journal of Medicine, vol. 341, no. 20, pp. 1485–1490, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Schmidt, H. Schmidt, J. D. Curb, K. Masaki, L. R. White, and L. J. Launer, “Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study,” Annals of Neurology, vol. 52, no. 2, pp. 168–174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Engelhart, M. I. Geerlings, J. Meijer et al., “Inflammatory proteins in plasma and the risk of dementia: the rotterdam study,” Archives of Neurology, vol. 61, no. 5, pp. 668–672, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Das and A. Basu, “Inflammation: a new candidate in modulating adult neurogenesis,” Journal of Neuroscience Research, vol. 86, no. 6, pp. 1199–1208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. L. Marsland, P. J. Gianaros, S. M. Abramowitch, S. B. Manuck, and A. R. Hariri, “Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults,” Biological Psychiatry, vol. 64, no. 6, pp. 484–490, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. McAfoose and B. T. Baune, “Evidence for a cytokine model of cognitive function,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 3, pp. 355–366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. O. Chaney, J. Baudry, C. Esh et al., “Aβ, aging, and Alzheimer's disease: a tale, models, and hypotheses,” Neurological Research, vol. 25, no. 6, pp. 581–589, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. B. De Strooper and G. König, “Alzheimer's disease: a firm base for drug development,” Nature, vol. 402, no. 6761, pp. 471–472, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. Selkoe, “Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein,” Annals of the New York Academy of Sciences, vol. 924, pp. 17–25, 2000. View at Google Scholar · View at Scopus
  29. M. A. Findeis, “The role of amyloid β peptide 42 in Alzheimer's disease,” Pharmacology and Therapeutics, vol. 116, no. 2, pp. 266–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Bentahir, O. Nyabi, J. Verhamme et al., “Presenilin clinical mutations can affect γ-secretase activity by different mechanisms,” Journal of Neurochemistry, vol. 96, no. 3, pp. 732–742, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Fukuyama, T. Mizuno, T. Mizuno et al., “Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer's disease patients,” European Neurology, vol. 43, no. 3, pp. 155–160, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Hansson, H. Zetterberg, P. Buchhave et al., “Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment,” Dementia and Geriatric Cognitive Disorders, vol. 23, no. 5, pp. 316–320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Yaffe, A. Weston, N. R. Graff-Radford et al., “Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline,” The Journal of the American Medical Association, vol. 305, no. 3, pp. 261–266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Bottiglieri and K. Hyland, “S-adenosylmethionine levels in psychiatric and neurological disorders: a review,” Acta Neurologica Scandinavica, vol. 89, supplement 154, pp. 19–26, 1994. View at Google Scholar · View at Scopus
  35. L. D. Morrison, D. D. Smith, and S. J. Kish, “Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease,” Journal of Neurochemistry, vol. 67, no. 3, pp. 1328–1331, 1996. View at Google Scholar · View at Scopus
  36. F. Tchantchou, M. Graves, D. Ortiz, A. Chan, E. Rogers, and T. B. Shea, “S-adenosyl methionine: a connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer's disease,” Journal of Nutrition, Health and Aging, vol. 10, no. 6, pp. 541–544, 2006. View at Google Scholar · View at Scopus
  37. C. G. Trolin, B. Regland, and L. Oreland, “Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders,” European Neuropsychopharmacology, vol. 5, no. 2, pp. 107–114, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Bottiglieri, P. Godfrey, T. Flynn, M. W. P. Carney, B. K. Toone, and E. H. Reynolds, “Cerebrospinal fluid S-adenosylmethionine-in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 53, no. 12, pp. 1096–1098, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. A. C. Pfalzer, S.-W. Choi, S. A. Tammen et al., “S-adenosylmethionine mediates inhibition of inflammatory response and changes in DNA methylation in human macrophages,” Physiological Genomics, vol. 46, no. 17, pp. 617–623, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Gobejishvili, D. V. Avila, D. F. Barker et al., “S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 2, pp. 433–443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Purohit, M. F. Abdelmalek, S. Barve et al., “Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium,” American Journal of Clinical Nutrition, vol. 86, no. 1, pp. 14–24, 2007. View at Google Scholar · View at Scopus
  42. B. Sharma and N. Singh, “Salutary effect of NFκB inhibitor and folacin in hyperhomocysteinemia-hyperlipidemia induced vascular dementia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 38, no. 2, pp. 207–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. P. J. Connelly, N. P. Prentice, G. Cousland, and J. Bonham, “A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease,” International Journal of Geriatric Psychiatry, vol. 23, no. 2, pp. 155–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. T.-F. Chen, R.-F. S. Huang, S.-E. Lin, J.-F. Lu, M.-C. Tang, and M.-J. Chiu, “Folic acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model,” Journal of Alzheimer's Disease, vol. 20, no. 2, pp. 607–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. T. B. Shea, J. Lyons-Weiler, and E. Rogers, “Homocysteine, folate deprivation and Alzheimer neuropathology,” Journal of Alzheimer's Disease, vol. 4, no. 4, pp. 261–267, 2002. View at Google Scholar · View at Scopus
  46. C. E. Creeley, D. F. Wozniak, A. Nardi, N. B. Farber, and J. W. Olney, “Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain,” Neurobiology of Aging, vol. 29, no. 2, pp. 153–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Atri, L. W. Shaughnessy, J. J. Locascio, and J. H. Growdon, “Long-term course and effectiveness of combination therapy in Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 22, no. 3, pp. 209–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. O. L. Lopez, J. T. Becker, A. S. Wahed et al., “Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 6, pp. 600–607, 2009. View at Publisher · View at Google Scholar · View at Scopus